Accueil/Actions/FDMT

FDMT

USD

4D Molecular Therapeutics Inc. Common Stock

$10.500-0.520 (-4.719%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$11.020

Haut

$11.020

Bas

$10.040

Volume

0.63M

Fondamentaux de l'Entreprise

Capitalisation Boursière

578.4M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.80M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $2.235Actuel $10.500Haut $12.34

Actualités Connexes

31 oct. 2025 · 03:02

GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

21 oct. 2025 · 14:28

Analyst Upgrades

RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target

RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics with a Outperform and maintains $26 price target.

RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target

14 oct. 2025 · 12:00

GlobeNewswire

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with